secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2022-11-22T23:59:59+00:00
Accession:  0001104659-22-121225
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics CEO Neal Walker to step down, becomes Chair; CFO Ruffo retires; Manion named CEO, Balthaser CFO
--------------------------------------------------------------------------------

- Neal Walker resigns as CEO effective Dec 31, 2022; appointed Chair of the Board effective Jan 1, 2023.
- CFO Frank Ruffo retires effective Dec 31, 2022; will serve as consultant through March 2, 2023.
- Douglas Manion, currently President, appointed CEO and Class I Director effective Jan 1, 2023.
- Kevin Balthaser, VP Finance since 2022, appointed CFO effective Jan 1, 2023.
- Christopher Molineaux becomes Lead Independent Director effective Jan 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465922121225/0001104659-22-121225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465922121225/tm2231125d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-121225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer